Smith Douglas Homes Corp. SDHC 深 滬
等待開盤 08-20 09:30:00 美东时间
20.53
+0.210
+1.03%
華盛通- 最 高20.885
- 今 開20.46
- 成交量 4.34万股
- 最 低 20.35
- 昨 收 20.32
- 總市值 1.85亿
- 52周最高 39.50
- 市盈率 靜 11.30
- 換手率 0.48%
- 52周最低 16.28
- 委 比 33.33%
- 總股本 899.14万
- 歷史最高 39.50
- 量 比 0.52
- 振 幅 2.63%
- 歷史最低 16.28
- 每 手 1
- 風險率 7.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Smith Douglas Homes Reports Modest Q2 Growth
Smith Douglas Homes Corp. Class A ( ($SDHC) ) has released its Q2 earnings. Her...
08-07 13:27
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Smith Douglas Homes announces stock repurchase program
Smith Douglas Homes (NYSE:SDHC) said on Wednesday that its board has authorized a stock repurchase program for up to $50M of the company’s Class A common stock. The company currently expects to fund t...
05-29 04:14
美股大行评级 | 潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
05-21 16:44
12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session
Gainers Big 5 Sporting Goods (NASDAQ:BGFV) shares moved upwards by 8.3% to $1....
05-21 05:06
RBC Capital Reiterates Sector Perform on Smith Douglas Homes, Lowers Price Target to $16
RBC Capital analyst Mike Dahl reiterates Smith Douglas Homes (NYSE:SDHC) with a Sector Perform and lowers the price target from $21 to $16.
05-20 22:10
Smith Douglas Homes reports Q1 results
Smith Douglas Homes press release (NYSE:SDHC): Q1 GAAP EPS of $0.30 Home closings increased 19% to 671 Home closing revenue increased 19% to $224.7 million Home closing gross margin of 23.8% compared ...
05-14 19:16
Earnings Scheduled For May 14, 2025
Companies Reporting Before The Bell • Cellebrite DI (NASDAQ:CLBT) is expected t...
05-14 16:32
美股大行评级 | 潜在涨幅506.8%！HC Wainwright & Co.上调Verve Therapeutics目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1118823510909566976.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Verve Therapeutics(VERV)"买入"评级，目标价从15美元升至25美元</p> <p>• Piper Sandler：维持LENZ Therapeut
04-15 11:35
